SJP 1602
Alternative Names: SJP-1602Latest Information Update: 28 Jul 2024
At a glance
- Originator Samjin Pharmaceutical Company
- Class Antineoplastics; Small molecules
- Mechanism of Action Focal adhesion protein tyrosine kinase inhibitors; Proline-directed protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in Cancer in South Korea (PO)
- 10 Apr 2021 Preclinical pharmacodynamics data in Colorectal cancer presented at the 112th Annual Meeting of the American Association for Cancer Research (AACR-2021)
- 22 Jun 2020 Preclinical trials in Cancer in South Korea (PO) before June 2020